Novo Nordisk Launches Wegovy Weight Loss Injection in the U.K.
Novo Nordisk has launched its Wegovy weight loss injection in the U.K., despite ongoing supply constraints. The Danish pharmaceutical company has initiated a controlled and limited launch of the weekly injection, making it available initially to certain patients on the country’s National Health Service (NHS). To qualify for treatment, patients must be enrolled in the NHS weight management service, have at least one weight-related condition, and have a body mass index of 35. The drug will also be available privately through registered healthcare professionals.
The cost of the drug in the U.K. has not been disclosed by Novo Nordisk. In the U.S., Wegovy is priced at $1,350 for a monthly dose, while in Europe it retails for around 170 to 300 euros per month. British insurance company Aviva has stated that Wegovy will not be covered under its private health insurance policy.
‘Closely Monitoring’ Supply Issues
Wegovy’s expansion into the U.K. follows its recent launch in Germany. The drug’s increasing demand and positive clinical studies highlighting its health benefits have boosted Novo Nordisk’s shares to record highs, briefly making it Europe’s most valuable company. However, supply constraints continue to impact the drug’s rollout. Novo Nordisk has allocated a portion of the available supply specifically for NHS treatment and is working with healthcare professionals to prioritize patients with the highest unmet medical need. The company is closely monitoring demand and collaborating with regulators and healthcare providers to ensure access to treatment for individuals living with obesity.
Novo Nordisk has also implemented limitations on the drug’s provisions in other markets. In the U.S., it reduced the supply of starter doses to ensure continuity for existing patients, while in Germany, doctors were advised to prescribe responsibly, limiting prescriptions to patients with medical needs.